1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Semaglutide Might Treat Heart Failure Directly

 
• By Elizabeth Cairns

Novo Nordisk’s product’s reputation as a wonder drug grows as new data suggest it might be disease-modifying in heart failure.    

Heart made out of red puzzle pieces with one piece missing
• Source: Shutterstock

Novo Nordisk A/S’s metabolic monster, semaglutide, is already under review at the US Food and Drug Administration to add heart failure to its litany of approved indications. Data presented at the weekend will add impetus to the argument for its approval, and intriguingly, the STEP-HFpEF DM study suggests that the GLP-1 agonist could treat heart failure over and above its weight loss effects alone.

Key Takeaways
  • Semaglutide has succeeded in a trial in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes

The study tested semaglutide in 616 patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Seven Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 
• By Alaric DeArment

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.

Vedanta’s Live Bacteria Reach A Dead End In Ulcerative Colitis

 
• By Andrew McConaghie

The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

More from R&D

Post-GLP-1 Patients Are Significant Opportunity, But Response Sees More

 
• By Alaric DeArment

The company will move ahead in testing RDX-002 among overweight and obese patients coming off GLP-1s, but the CEO said antipsychotic-induced weight gain could represent a multibillion-dollar market.

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.